bin kontan/iStock via Getty Images Advanced Biomed ( ADVB ), a medtech company focused on assay products and services for cancer, has dramatically downsized its proposed initial public offering from around $112.5M to $9.4M.
In its latest SEC filing , Advanced Biomed ( ADVB ) said it was.